NK:IO is an Imperial spinout developing small molecule and cell-mediated immunotherapy for the treatment of
The company is developing techniques aimed at increasing the potential of natural killer cells for use in
immunotherapies for cancer. The company is validating its proof of concept studies after many years of work on
natural killer cell biology. It has progressed through the Start Codon accelerator.